The pivotal phase III study with the L-praziquantel pediatric oral dispersible tablets (ODTs) has started, shortly after establishing the recommended dose and encouraging results of the phase II study in pediatric schistosomiasis.

With the Phase III clinical trial protocol locally approved, the trial has started.

The Pediatric Praziquantel Consortium looks back on a very inspiring and successful Consortium meeting in Kisumu, the third largest city in Kenya located by the shore of Lake Victoria.

With the implementation of the Phase III clinical trial, the Pediatric Praziquantel (PZQ) Consortium Formulation program is approaching its final objective of providing access to the new drug for patients.

The fourth research grant from the Global Health Innovative Technology (GHIT) Fund provides further support for the development, registration and access of a pediatric praziquantel orally dispersible tablet for preschool-age children infected with schistosomiasis.

Consortium partners will participate at the 11th European Congress on Tropical Medicine and International Health (ECTMIH) on September 16-20, 2019, in Liverpool (UK).

The Pediatric Praziquantel Consortium was featured in the first issue of the Japan Alliance on Global Neglected Tropical Diseases (JAGntd) newsletter.

The fourth research grant from the Global Health Innovative Technology (GHIT) Fund provides further support for the development, registration and access of a pediatric praziquantel orally dispersible tablet for preschool aged children infected with schistosomiasis.

The Pediatric Praziquantel Consortium marks the World Health Day through its continuous effort to register and launch a child-friendly and new praziquantel formulation for preschool-age children suffering from schistosomiasis. 

Consortium partners have been interacting with the local community in Ivory Coast and with experts from all over the world in Thailand to pave the way for an appropriate access path for the new pediatric drug

In January 2019, researchers from the Pediatric Praziquantel Consortium published the results of two Phase I pharmacokinetic studies in healthy adult volunteers. 

The important milestone of Last Patient Last Visit (LPLV) in the clinical Phase II trial was achieved on November 17, 2018

On 20 November 2018, Astellas Pharma Inc. announced the launch of the Astellas Global Health Foundation (AGHF): a new international philanthropic organization dedicated to improving access to health in underserved global communities.

With the Phase II trial showing good results on safety and efficacy for the new orally dispersible praziquantel tablets, the Consortium has entered the pivotal Phase III stage